The correct classification: Pure GLP-1 agonists: exenatide, liraglutide, lixisenatide, dulaglutide, semaglutide, efpeglenatide, orforglipron Dual GIP/GLP-1 agonists: tirzepatide Triple agonists (GIP/GLP-1/glucagon): retatrutide Retatrutide, approved in early 2026, adds glucagon receptor agonism to the dual GIP/GLP-1 mechanism
This approach helps mitigate potential issues and ensures ongoing support for your health goals
Clinically, several GLP-1 RAs are approved or under study for obesity
Bodnaruc et al 2016), compared to the GLP-1 medications with a half-life of 7 days
Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes
Note that your fluid needs may increase if you are physically active or sweating heavily